Parenteral Iron Administration Regimen

Indications for Parenteral Iron

The National Comprehensive Cancer Network recommends that parenteral iron be reserved for patients who cannot maintain adequate iron status with oral supplements, especially in cases of long-term parenteral nutrition 1, 2
The National Comprehensive Cancer Network does not recommend routine administration of iron in short-term parenteral nutrition (<3 weeks) 1, 2
Patients with active infection should not receive intravenous iron therapy, as recommended by the National Comprehensive Cancer Network 3, 4

The dosing regimen for iron sucrose is 200 mg IV over 60 minutes (infusion) or 200 mg over 2-5 minutes (slow IV bolus), with repeated administration every 2-3 weeks until the total required dose is achieved, as recommended by the National Comprehensive Cancer Network 3, 5
The maximum individual dose should not exceed 300 mg, and the maximum total dose should be 1000 mg, as recommended by the National Comprehensive Cancer Network 3, 4, 5
Iron sucrose has been extensively studied in children, with rare serious adverse events, and is approved in the US for use in children aged 2 years and older 6, 7

The dosing regimen for ferric gluconate is 125 mg IV over 60 minutes, with weekly administration for 8 doses, as recommended by the National Comprehensive Cancer Network 3, 4
The maximum individual dose should not exceed 125 mg, and the maximum total dose should be 1000 mg, as recommended by the National Comprehensive Cancer Network 3, 4

The dosing regimen for iron dextran is 100 mg IV over 5 minutes, with weekly administration for 10 doses to achieve a total dose of 1 g, or infusion of the total dose over several hours, as recommended by the National Comprehensive Cancer Network 3, 4
A test dose is mandatory, with 25 mg administered as a slow IV bolus and waiting 1 hour before administering the main dose, as recommended by the National Comprehensive Cancer Network 3, 4

Iron status (at least ferritin and hemoglobin) should be regularly monitored in patients with long-term parenteral nutrition, as recommended by Clinical Nutrition 1, 2, 7
Common adverse reactions associated with parenteral iron preparations include hypotension, hypertension, nausea, vomiting, diarrhea, pain, fever, dyspnea, pruritus, headache, and dizziness, as reported by the National Comprehensive Cancer Network 3, 4

In oncologic patients receiving erythropoiesis-stimulating agents (ESAs), parenteral iron has been shown to be useful in treating functional iron deficiency, as recommended by the National Comprehensive Cancer Network 3, 4
Iron dextran at a concentration of 100 mg/L is stable for up to 18 hours at room temperature in lipid-free parenteral nutrition solutions, as reported by Clinical Nutrition 7
Iron dextran should not be added to lipid emulsions or all-in-one mixtures, as it destabilizes the emulsion, as reported by Clinical Nutrition 7
Iron sucrose has been shown to be stable in lipid-free parenteral nutrition solutions at concentrations up to 2.5 mg/L, as reported by Clinical Nutrition 7

Iron sucrose does not require a test dose before administration, unlike iron dextran, as recommended by the National Comprehensive Cancer Network 8
Test doses are strongly recommended at physician discretion if patients have exhibited sensitivities to iron dextran or other IV iron preparations, or who have multiple drug allergies, with a recommended 25 mg test dose administered as a slow IV push 8

Patients with documented hypersensitivity to iron dextran may experience hypotension or hypertension, and should be monitored accordingly 8

The European Society of Cardiology notes that dizziness, headache, hypertension, hypophosphataemia, injection-site reactions, and nausea are common adverse effects of iron sucrose therapy, with dizziness and hypophosphataemia being reported in clinical trials and post-marketing surveillance 9
The National Comprehensive Cancer Network recommends monitoring for headache and hypertension as common adverse effects of iron sucrose therapy 10
Clinical Nutrition reports that nausea is a common adverse effect of iron sucrose therapy 11

The European Journal of Heart Failure states that hypersensitivity reactions, including anaphylactic-type reactions, have been reported with iron sucrose, with a frequency of ≥0.1% to <1% during clinical trials and post-marketing surveillance 9
The American Journal of Kidney Diseases notes that delayed reactions characterized by arthralgias and myalgias are dose-related and rarely occur with doses of 100 mg or less 12

Clinical Nutrition reports that iron sucrose is the most extensively studied IV iron preparation in children, with rare serious adverse events, and no anaphylactic reactions occurred in a randomized study of 145 children, adolescents, and young adults 13, 11

The National Comprehensive Cancer Network states that iron sucrose and iron gluconate are considered to have significantly fewer adverse effects than iron dextran, with iron dextran carrying a "black-box" warning and requiring a mandatory test dose due to risk of anaphylactic reactions 10
The American Journal of Kidney Diseases notes that life-threatening anaphylactoid reactions are markedly lower with iron sucrose compared to iron dextran 12

The National Comprehensive Cancer Network recommends not administering iron sucrose to patients with active infection, due to concerns about promoting inflammation and bacterial growth 10